References
- Paulose-Ram R, Hirsch R, Dillon C, et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003;12:315-26
- Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-9
- Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase-III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374:119-25
- Taha AS, Kelly C, McCloskey C, et al. Gastroprotective policy and the incidence of upper gastrointestinal bleeding. Frontline Gastroenterology 2013;4:108-11
- Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual patient data from randomised trials. Lancet 2013;382:769-79
- Laine L, Kivitz AJ, Bello AE, et al, on behalf of the REDUCE-1 and -2 Study Investigators. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379-86
- Bello AE, Grahn AY, Ball J, et al. 1-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. Curr Med Res Opin 2015
- Bello A, Kent J, Grahn A, et al. One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. Curr Med Res Opin 2015